Wang Tongtong, Liu Yingchu, Zhu Chunyu, Yang Siyuan, Yang Di, Xiao Jiang, Gao Guiju
Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
School of General Practice and Continuing Education, Capital Medical University, Beijing, People's Republic of China.
Infect Drug Resist. 2023 Jul 17;16:4659-4666. doi: 10.2147/IDR.S415749. eCollection 2023.
Rifampicin is a known inducer of the cytochrome P450 (CYP2B6) enzyme, which can lead to a decrease in the concentration of efavirenz. Therefore, we conducted a study to evaluate the effect of daily rifampicin intake on efavirenz 600mg pharmacokinetics and HIV-1 virological suppression.
Patients receiving antiretroviral therapy containing efavirenz (600mg daily), and we collected efavirenz concentration at four visit points: ART day 14 (PK1), ART day 42 (PK2), ART day 140 (PK3), and ART day 336 (PK4), and performed pharmacokinetics analysis.
From February 2017 to November 2020, 29 HIV/TB co-infection patients were included. Ninety percent of patients had a concentration of ≥1000ng/mL of efavirenz during the study. All patients had efavirenz C ≥1000ng/mL, 86% patients showed good virology response.
Our study shows that the use of rifampicin in HIV/TB co-infection patients does not affect efavirenz drug concentrations, that virological suppression is good and that no efavirenz dose adjustment is required.
利福平是一种已知的细胞色素P450（CYP2B6）酶诱导剂，可导致依非韦伦浓度降低。因此，我们开展了一项研究，以评估每日服用利福平对600mg依非韦伦药代动力学及HIV-1病毒学抑制的影响。
患者接受含依非韦伦（每日600mg）的抗逆转录病毒治疗，我们在四个访视点收集依非韦伦浓度：抗病毒治疗第14天（PK1）、抗病毒治疗第42天（PK2）、抗病毒治疗第140天（PK3）和抗病毒治疗第336天（PK4），并进行药代动力学分析。
2017年2月至2020年11月，纳入29例HIV/TB合并感染患者。90%的患者在研究期间依非韦伦浓度≥1000ng/mL。所有患者依非韦伦C≥1000ng/mL，86%的患者显示出良好的病毒学反应。
我们的研究表明，在HIV/TB合并感染患者中使用利福平不影响依非韦伦药物浓度，病毒学抑制良好，且无需调整依非韦伦剂量。
